{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:52:39Z","timestamp":1788821559934,"version":"build-2803163510"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T00:00:00Z","timestamp":1402012800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0098865","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T20:24:59Z","timestamp":1402086299000},"page":"e98865","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":60,"title":["Comparison of Efficacy and Safety of Tenofovir and Entecavir in Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis"],"prefix":"10.1371","volume":"9","author":[{"given":"Weixia","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shudong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,6,6]]},"reference":[{"key":"ref1","first-page":"545","article-title":"Hepatitis B today","volume":"54","author":"M Safioleas","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"D Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"ref3","first-page":"1118","article-title":"Hepatitis B virus infection natural history and clinical consequences. N. Engl","volume":"350","author":"D Ganem","year":"2004","journal-title":"J. Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"For the chronic hepatitis B guideline workshop party of the Asian-Pacific Association For The Study Of The Liver. Asian-Pacific consensusstatement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"YF Liaw","year":"2008","journal-title":"Hepatol Int"},{"key":"ref5","first-page":"1","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"ASF Lok","year":"2009","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"Clinical practice guidelines: management of chronic hepatitis B.","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"ref7","first-page":"320","article-title":"Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries. Natl. Med","volume":"15","author":"R Aggarwal","year":"2002","journal-title":"J. India"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2036.2008.03731.x","article-title":"Review article: current antiviral therapy of chronic hepatitis B.","volume":"28","author":"SB Ayoub","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.22658","article-title":"Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir","volume":"49","author":"N Leung","year":"2009","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"DJ Tenney","year":"2009","journal-title":"Hepatology"},{"key":"ref11","first-page":"A88","article-title":"Entecavir at five years show long term maintenance of high genetic barrier to hepatitis B virus resistance","volume":"2","author":"DJ Tenny","year":"2008","journal-title":"Hepatol Int"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.","volume":"140","author":"EJ Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/gut.2010.223206","article-title":"Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.","volume":"60","author":"SJ Patterson","year":"2011","journal-title":"Gut"},{"key":"ref14","first-page":"S","article-title":"Tenofovir is more effective than Entecavir for achieving rapid viral suppression in HBeAg-Positive chronic hepatitis B patients with high HBV DNA levels","volume":"144","author":"L Gao","year":"2013","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","article-title":"Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses","volume":"139","author":"G Woo","year":"2010","journal-title":"Gastroenterology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","article-title":"Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease","volume":"53","author":"YF Liaw","year":"2011","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"S695","DOI":"10.1016\/S0016-5085(12)62685-7","article-title":"Efficacy and safety of Entecavir versus Tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial","volume":"1421","author":"T Sriprayoon","year":"2012","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cgh.2012.10.003","article-title":"Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis","volume":"11","author":"S Koklu","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4318\/tjg.2012.0380","article-title":"Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.","volume":"23","author":"UB Dogan","year":"2012","journal-title":"Turk J Gastroenterol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S930","DOI":"10.1016\/S0016-5085(11)63860-2","article-title":"Comparison of the efficacy of Entecavir and Tenofovir in chronic hepatitis B patients with high viral load and\/or high fibrosis scores at week 48 of therapy","volume":"140","author":"O Kurdas","year":"2011","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/0974-2727.98664","article-title":"Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir","volume":"4","author":"R Jayakumar","year":"2012","journal-title":"J Lab physicians"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"AR Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"ref23","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"N Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6(6)","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1128\/JVI.02395-06","article-title":"Inhibition of hepatitis B virus polymerase by entecavir","volume":"81","author":"DR Langley","year":"2007","journal-title":"J Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/jac\/dkr388","article-title":"Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B.","volume":"66","author":"J Fung","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref28","first-page":"A409","article-title":"A viral load reduction > 3 log at 12 week of Entecavir treatment correlated with HBe seroconversion in HBeAg positive patients. Results from a real-life setting study","volume":"52","author":"M Buti","year":"2010","journal-title":"Hepatology"},{"key":"ref29","first-page":"A1436","article-title":"Entecavir monotherapy for nuc-na\u00efve chronic hepatitis B patients from field practice: high efficacy and favorable safety profile over 3 year","volume":"54","author":"P Lampertico","year":"2011","journal-title":"Hepatology"},{"key":"ref30","first-page":"A1396","article-title":"Denovo antiviral therapy with nucleos(t)ide analogues in \u2018real-life\u2019 patients with chronic hepatitis B infection: comparison of virological response between lamivudine + adefovir, entecavir vs. tenofovir therapy","volume":"54","author":"I Carey","year":"2011","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1742-1241.2011.02719.x","article-title":"Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice","volume":"65","author":"E Ridruejo","year":"2011","journal-title":"Int J Clin Prac"},{"key":"ref32","first-page":"A1433","article-title":"2 year effectiveness and safety of tenofovir in 302 NUC-na\u00efve patients with chronic hepatitis B: a multicenter European study in clinical practice","volume":"54","author":"P Lampertico","year":"2011","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-1746.2010.06541.x","article-title":"The clinical implications of hepatitis B virus genotype: Recent advances","volume":"26","author":"CL Lin","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1002\/hep.22885","article-title":"Side effects of long-term oral antiviral therapy for hepatitis B.","volume":"49","author":"RJ Fontana","year":"2009","journal-title":"Hepatology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1756283X09354562","article-title":"Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.","volume":"3","author":"A Duarte-Rojo","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"key":"ref36","first-page":"145A","article-title":"Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate treatment in HBeAg-negative patients with chronic hepatitis B (study 102): preliminary analysis","volume":"52","author":"P Marcellin","year":"2010","journal-title":"Hepatology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.","volume":"140","author":"EJ Heathcote","year":"2010","journal-title":"Gastroenterology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"F Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"Bommel Van","year":"2010","journal-title":"Hepatology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jhep.2010.01.012","article-title":"Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues","volume":"52","author":"JG Reijnders","year":"2010","journal-title":"J Hepatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1440-1746.2008.05760.x","article-title":"Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?","volume":"24","author":"Y Suzuki","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s12072-009-9162-x","article-title":"Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B.","volume":"4","author":"Y Karino","year":"2010","journal-title":"Hepatol Int"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0168-8278(09)60022-2","article-title":"Entecavir maintain a high genetic barrier to HBV resistance through 6 years in na\u00efve patients","volume":"50","author":"DJ Tenney","year":"2009","journal-title":"J. Hepatol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/1743-422X-8-393","article-title":"Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis","volume":"8","author":"YJ Sheng","year":"2011","journal-title":"Virol J"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/egh.12.52","article-title":"Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs","volume":"6","author":"J Petersen","year":"2012","journal-title":"Expert Rev Gastroenterol Hepatol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0098865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T10:01:39Z","timestamp":1565517699000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0098865"}},"subtitle":[],"editor":[{"given":"Xiaoping","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,6]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0098865","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,6]]}}}